Cartesian Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Cartesian Therapeutics, Inc. reports a director's resignation and a significant conversion of preferred stock to common stock by a major stakeholder.
NASDAQ
SCHEDULE 13D/A: Cartesian Therapeutics Director Timothy Springer Significantly Increases Stake to 36.9%
Timothy A. Springer, a director of Cartesian Therapeutics, Inc., has substantially increased his beneficial ownership in the company to 36.9% through recent open market purchases and equity grants.